Rubicon Organics Inc.

Rubicon Organics Inc. Earnings Recaps

ROMJ.V Health Care 1 recap
Next earnings: November 18, 2026 (estimated) · full calendar
Q2 2026 Aug 15, 2026

Rubicon Organics shares dropped 8.0% following the earnings release as investors reacted negatively to cautious outlook commentary and ongoing margin pressure despite notable revenue growth.

Key takeaways
  • Q2 revenue hit a record $18.5 million, up 23% year-over-year and 35% sequentially, driven primarily by yield improvements at the Pacifica facility and initial revenue from Cascadia.
  • Gross margin before fair value adjustments was 30%, or 36% excluding pre-revenue Cascadia costs; margin expansion remains a work in progress amid ongoing investments.
  • Adjusted EBITDA stayed positive at $1.1 million but declined year-over-year, reflecting higher SG&A costs supporting brand development and international expansion.
  • Cascadia contributed $450 thousand in revenue late in Q2, with yield optimization continuing as a key focus for future quarters.
  • Management signaled expectations for revenue and EBITDA to ramp in H2 2026 but highlighted ongoing investments and margin pressure, dampening near-term optimism.